Sound Pharmaceuticals, Incorporated
14
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
14%
2 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Role: lead
SPI-1005 in Adults Receiving Cochlear Implant
Role: lead
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
Role: lead
SPI-1005 for the Treatment of Meniere's Disease
Role: lead
SPI-1005 Treatment in Moderate COVID-19 Patients
Role: lead
SPI-1005 Treatment in Severe COVID-19 Patients
Role: lead
SPI-1005 for the Treatment of Patients With Meniere's Disease
Role: lead
IMPase in Treatment-resistant Depression
Role: collaborator
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
Role: lead
Ebselen as an add-on Treatment in Hypo/Mania
Role: collaborator
A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss
Role: lead
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Role: lead
Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
Role: lead
Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift
Role: lead
All 14 trials loaded